nivolumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
pharma · Gastric Cancer · Colorectal Cancer
Ono Pharmaceutical
Ono Pharmaceutical Co.,
Ono Pharmaceutical drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Osaka, JP HQ
441 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Osaka, JP
- Employees
- 441
- Programs
- 4
- Drugs
- 2
- Patents
- 0
Ono Pharmaceutical pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Ono Pharmaceutical drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Ono Pharmaceutical in public FDA and regional records.